Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here. 		You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
TOP SEARCHES: OCT // Canaloplasty // AMD
In this issue
• ?????????????
• Microplsamin potential
• Non-infectious uveitis
• VEGF
• Glaucoma
• Wet AMD
Survey

What’s your view of the Novartis/Alcon merger?
Novartis

Good for ophthalmology 30%
Bad for
ophthalmology 		15%
Primarily in the interests of shareholders 45%
No view 10%

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Pamela Brook, editor.

Click here to contact Neil Hanley, sales manager.
FEBRUARY 24, 2010
>
VEGF Trap-Eye shows positive results in a phase 2 study in patients with diabetic macular oedema
VEGF Trap-Eye, the fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PIGF), has shown positive results in a Phase 2 study in patients with diabetic macular oedema (DME). More...
Potential of microplsamin to improve the treatment of a range of back of the eye diseases
A paper entitled “A Placebo-Controlled Trial of Microplasmin Intravitreous Injection to Facilitate Posterior Vitreous Detachment Before Vitrectomy” has been published online ahead of print in Ophthalmology. It covers the Phase II trial (MIVI III) with microplasmin, with the objective of evaluating the efficacy and safety of intravitreal microplasmin in facilitating the separation of the vitreous from the retina. More...
EMA approval sought for non-infectious uveitis drug
LUVENIQ (LX211; oral voclosporin) has been filed for approval by the European Medicines Agency (EMA) and the US’s Food and Drug Administration by Lux Biosciences. The drug is aimed at treatment of non-infectious uveitis for the intermediate or posterior segments of the eye. More...
Anti-VEGF for AMD a top advancement
Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advancement in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December. More...
Glaucoma medications associated with lower mortality
Researchers in the journal, Archives of Ophthalmology have indicated that results from a 4-year study of more than 21,000 Americans point to an association between glaucoma medications and a lower death rate. More...
Wet AMD drug enters Phase I trial
Palomid 529 (P529) is to enter its Phase I trial in patients with AMD. A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients with Advanced Neovascular Age-Related Macular Degeneration will according to Paloma Pharmaceuticals, be a dose-ranging study for safety but will also have an objective measure for efficacy. More...
Also In This Issue...

 

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.

To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, please contact us by emailing magazines@superfill.com or by mail at Advanstar Communications, Advanstar House, Park West, Sealand Road, Chester, CH1 4RN, UK.